Skip to content
sellWeak cluster of 310b5-1 plan

Johanna Mercier sold $3.3M of GILD

Chief Commercial Officer at GILEAD SCIENCES, INC.. 28,000 shares at an average of $118.53, traded Aug 15, 2025, filed Aug 18, 2025.

Warning score
25
Value
$3.3M
28,000 shares
Holdings after
114,168
-22% from before
From 52-week low
+51%
low $75.99, close $114.72
From 52-week high
-2%
high $116.75, as of Aug 15, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $3.3M at market
    +25
  • Share of holdings sold
    Sold 22% of holdings
    +5
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

GILDOct 9, 2026 · close 151.17
Since filing Aug 18, 2025: +32.2%SPY +22.7% · excess +9.5%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000882095-25-000037, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Aug 15, 2025MOption exercise
Common Stock10b5-1
+11,800$66.64$786k128,968Aug 18, 2025
Aug 15, 2025SOpen-market sale
Common Stock10b5-1
-11,800$118.50$1.4M117,168Aug 18, 2025
Aug 15, 2025MOption exercise
Common Stock10b5-1
+700$66.64$47k117,868Aug 18, 2025
Aug 15, 2025SOpen-market sale
Common Stock10b5-1
-700$118.97$83k117,168Aug 18, 2025
Aug 15, 2025MOption exercise
Common Stock10b5-1
+11,800$66.64$786k128,968Aug 18, 2025
Aug 15, 2025SOpen-market sale
Common Stock10b5-1
-11,800$118.51$1.4M117,168Aug 18, 2025
Aug 15, 2025MOption exercise
Common Stock10b5-1
+700$66.64$47k117,868Aug 18, 2025
Aug 15, 2025SOpen-market sale
Common Stock10b5-1
-700$118.97$83k117,168Aug 18, 2025
Aug 15, 2025SOpen-market sale
Common Stock10b5-1
-2,800$118.51$332k114,368Aug 18, 2025
Aug 15, 2025SOpen-market sale
Common Stock10b5-1
-200$118.97$24k114,168Aug 18, 2025
Aug 15, 2025MOption exercise
Non-qualified Stock Option (Right to Buy)derivative10b5-1
-11,800$0.00$0111,310Aug 18, 2025
Aug 15, 2025MOption exercise
Non-qualified Stock Option (Right to Buy)derivative10b5-1
-700$0.00$0110,610Aug 18, 2025
Aug 15, 2025MOption exercise
Non-qualified Stock Option (Right to Buy)derivative10b5-1
-11,800$0.00$098,810Aug 18, 2025
Aug 15, 2025MOption exercise
Non-qualified Stock Option (Right to Buy)derivative10b5-1
-700$0.00$098,110Aug 18, 2025

Related signals

Other insiders at GILEAD SCIENCES, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
GILDsell10b5-1
GILEAD SCIENCES, INC.
Daniel Patrick O'Day
Chairman & CEO
$2.2M
15,000 shares
-3%
34Weak
GILDsell 310b5-1
GILEAD SCIENCES, INC.
Andrew D Dickinson
Chief Financial Officer
$436k
3,000 shares
-2%
27Weak
GILDsell 310b5-1
GILEAD SCIENCES, INC.
Johanna Mercier
Chief Comm & Corp Aff Officer
$433k
3,000 shares
-3%
45Moderate
GILDsell 310b5-1
GILEAD SCIENCES, INC.
Daniel Patrick O'Day
Chairman & CEO
$2.2M
15,000 shares
-3%
17Weak
GILDsell10b5-1
GILEAD SCIENCES, INC.
Andrew D Dickinson
Chief Financial Officer
$366k
3,000 shares
-2%
38Weak
GILDsell 2
GILEAD SCIENCES, INC.
Jeffrey Bluestone
director
$625k
5,000 shares
-36%
24Weak
GILDsell 210b5-1
GILEAD SCIENCES, INC.
Andrew D Dickinson
Chief Financial Officer
$313k
2,500 shares
-2%
16Weak
GILDsell10b5-1
GILEAD SCIENCES, INC.
Andrew D Dickinson
Chief Financial Officer
$295k
2,500 shares
-2%
45Moderate
GILDsell 310b5-1
GILEAD SCIENCES, INC.
Daniel Patrick O'Day
Chairman & CEO
$1.1M
10,000 shares
-2%
31Weak
GILDsell 310b5-1
GILEAD SCIENCES, INC.
Andrew D Dickinson
Chief Financial Officer
$284k
2,500 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Johanna Mercier sold $3.3M of GILD | InsiderTell